首页> 外文OA文献 >Molecular mechanisms of diabetic retinopathy, general preventive strategies and novel therapeutic targets
【2h】

Molecular mechanisms of diabetic retinopathy, general preventive strategies and novel therapeutic targets

机译:糖尿病性视网膜病变的分子机制,一般预防策略和新型治疗靶点

摘要

The growing number of people with diabetes worldwide suggests that DR and DME will continue to be sight threatening factors. The pathogenesis of diabetic retinopathy is a widespread cause of visual impairment in the world and a range of hyperglycemia-linked pathways have been implicated in the initiation and progression of this condition. Despite understanding the polyol pathway flux, activation of protein kinase C (KPC) isoforms, Igf-I signaling in response to hyperglycemia, increased hexosamine pathway plux and increased advanced glycation end-product (AGE) formation, pathogenic mechanisms underlying diabetes induced vision loss are not fully understood. More than 50 years of its introduction, destruction of damaged retina by photocoagulation remains the primary treatment among the physicians. Scatter or panretinal laser photocoagulation is risky while Intensive glycemic and blood pressure control procedures are hard to manage on daily bases. This review highlights the recent advancements in understanding hyperglycemia-induced biochemical and molecular alterations, systemic metabolic factors and aberrant activation of signaling cascades that ultimately lead to activation of a number of transcription factors causing functional and structural damage to retinal cells. It also reviews the established interventions and emerging molecular targets to avert diabetic retinopathy and its associated risk factors.
机译:世界范围内糖尿病患者的数量不断增加表明DR和DME将继续成为视力威胁因素。糖尿病性视网膜病的发病机理是世界范围内视力障碍的普遍原因,并且与高血糖相关的一系列途径与这种疾病的发生和发展有关。尽管了解多元醇途径通量,蛋白激酶C(KPC)亚型的激活,对高血糖症的应答Igf-I信号传导,己糖胺途径通量增加和晚期糖基化终产物(AGE)形成增加,糖尿病引起视力丧失的致病机制仍在尚未完全了解。引入光凝已有50多年了,光凝破坏受损的视网膜仍然是医师们的主要治疗方法。散射或全视网膜激光光凝有危险,而强化血糖和血压控制程序很难每天进行管理。这篇综述强调了在了解高血糖引起的生化和分子改变,系统性代谢因子和信号级联反应的异常激活方面的最新进展,这些信号级联最终导致许多转录因子的激活,从而引起视网膜细胞功能和结构损伤。它还审查了避免糖尿病性视网膜病变及其相关危险因素的既定干预措施和新兴的分子靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号